As the coronavirus pandemic first spread across the globe, health systems turned to technology and virtual care while focusing their efforts on COVID-19 and its consequences. Physicians deployed digital tools to keep the worried well out of hospitals, to keep beds open for COVID-19 patients, and to support and manage conditions like pregnancy from the safety of patients’ homes.
Now the healthcare sector faces a new challenge. The so-called “Great Resignation” is causing workers to leave their
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
VivoSense Raises $25M for Wearable Sensor Biomarkers to Advance Clinical Trials
What You Should Know:
- VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series A funding.
- The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital
Read More
Why Mainstream Precision Medicine Hinges on Healthcare HPC Storage
The healthcare industry is experiencing a data deluge, and it shows no sign of slowing down.
In 2020, estimates reported that healthcare data comprised a staggering 30% of the world’s total data volume; projections for 2025 bump that number up to 36%, a growth rate outpacing every other industry.
This is promising news for precision medicine, the data-driven healthcare initiative that promotes the right treatment for the right patient at the right time.
Precision (or personalized)
Read More
Tempus Launches Pathology-Driven AI Platform
What You Should Know:
- Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide.
- With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would
Read More
physIQ, CellCarta Collaborate on Study to Revolutionize Vaccine
What You Should Know:
- Today, digital medicine leader physIQ and CellCarta, a global leader in precision medicine services announced they are collaborating on a groundbreaking study that could revolutionize vaccine development.
- The strategic collaboration advances the detailed study of early, individualized human responses to vaccinations as pharma companies race to deliver safe, effective vaccines sooner.
physIQ, a pioneer in digital medicine, and CellCarta, a global leader in
Read More
Precision Medicine Startup Prenosis Raises $20M for Acute Care Solutions, Starting with Sepsis
What You Should Know:
- Prenosis, Inc., a precision medicine company, announced a venture investment from PACE Healthcare Capital, an early-stage investment firm committed to improving health outcomes. This investment brings total funding in the company to over $20 million, including partnerships with Foxconn, Roche Diagnostics, the Defense Threat Reduction Agency, and others.
- Precision medicine company will use the funding to
Read More
Implementing Responsible AI to Drive Innovation in Clinical Research & Precision Medicine
Researchers might be skeptical and, with people’s lives at stake, that’s understandable. Here’s how to take advantage of the advances while ensuring safeguards are in place.
As artificial intelligence (AI) and machine learning drive innovation and disruption in clinical trials and precision medicine, questions around the responsible use of AI have moved to the forefront of debates among healthcare stakeholders – patients, providers, regulatory authorities, payors and sponsors. To what extent,
Read More
Syapse, Pfizer Extends Collaboration to Generate Real-World Evidence in Breast Cancer
What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer.
- This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021.
Generate Real-World Evidence in Breast Cancer
As part of the next phase of the collaboration, Syapse will provide insights and services to Pfizer, using the Syapse Learning Health Network
Read More
Notable Labs Launches by Acquiring Rights to Volasertib – Will Use Data, AI to Fast-Track Cancer Treatment
What You Should Know:
- Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes.
- Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development
Read More
Prenosis, Roche Partner to Combat Hospital Sepsis Using Precision Diagnostics
What You Should Know:
- Prenosis Inc., a precision diagnostics company transforming clinical diagnosis with artificial intelligence, announced today the expansion of an existing partnership with Roche Diagnostics that will total close to $6 million to improve and expedite the clinical recognition of sepsis.
- Building upon the collaboration that the companies started together in 2020, Prenosis will significantly expand its core NOSIS™ dataset, and the two companies will work together
Read More
